Abstract: The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis. In particular, the invention relates to such compositions for eliciting an immune response against antigens and pathogens involved in the development of atherosclerosis. The invention includes inter alia methods of treating and/or preventing the disease and recombinant protein products.

Abstract: The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis. In particular, the invention relates to such compositions for eliciting an immune response against antigens and pathogens involved in the development of atherosclerosis the invention includes inter alia methods of treating and/or preventing the disease and recombinant protein products.

Abstract: The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis.

Abstract: The invention relates to a recombinant protein comprising: a carrier portion; a first epitope capable of eliciting an anti-atheroma response; and a second epitope capable of eliciting an anti-atheroma response, characterized in that said first and second epitopes are distinct from one another.

Abstract: The invention relates to a recombinant protein comprising: a carrier portion; a first epitope capable of eliciting an anti-atheroma response; and a second epitope capable of eliciting an anti-atheroma response, characterised in that said first and second epitopes are distinct from one another.

Abstract: The invention relates to a recombinant Mycobacterium bovis which expresses at least one Chlamydophila pneumoniae antigen.

Abstract: Products which contain two interlinked functional moieties of which one is an integrin-binding protein (e.g. a snake venom protein) or a homologue thereof. The products comprise a first portion which is an integrin-binding protein, a homologue thereof having a binding activity or a fragment of either which has integrin-binding activity, and, ligated to the first portion, a second portion which has a different function.

Abstract: Dendroaspin, a polypeptide neurotoxin analogue is modified by recombinant DNA techniques, particularly “loop grafting” to provide a modified polypeptide. The modified polypeptide is constructed so as to retain dendroaspin activity, for example, platelet adhesion to fibrinogen, in addition to possessing one or more further biological or biochemical activities not native to dendroaspin, for example, platelet derived growth factor (PDGF) activity or hirudin activity.

Abstract: The use of dendroaspin as a scaffold for one or more non-wild-type dendroaspin domains, the dendroaspin scaffold being modified in that the native RGD motif has been deleted or has been replaced by (i) an amino acid sequence having no integrin-binding activity or (ii) an integrin-binding amino acid sequence other than RGD which contains aspartic acid (D) or glutamic acid (E).